Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tissue engineered heart valve to enter human trials:

This article was originally published in Clinica

Executive Summary

US company CryoLife plans to begin human trials of a new tissue-engineered heart valve which combines living human cells with a porcine heart valves to mimic more closely a natural human valve. The Atlanta, Georgia-based company plans to submit an investigational device exemption to the US FDA in the fourth quarter of 1999 for its SynerGraft technology. Last month, the company announced that SynerGraft porcine valves implanted in sheep were functional and showed no signs of calcification after 160 days.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT078467

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel